美罗华联合CHOP方案治疗侵袭性B细胞淋巴瘤

Rituximab Combined with CHOP Regimen in the Treatment of Aggressive B Cell Lymphoma

目的:探讨美罗华联合CHOP方案治疗侵袭性B细胞淋巴瘤疗效。方法:选取患者102例,采用数字表法分为常规组和联合组,分别给予CHOP方案和美罗华联合CHOP方案治疗,评价其治疗有效率和不良反应率。结果:联合组治疗有效性(88.24%)高于常规组(66.67%)(P<0.05);两组不良反应率(21.57%vs25.49%)差异对比无统计学意义(P>0.05)。结论:美罗华联合CHOP方案治疗侵袭性B细胞淋巴瘤相比于常规方案,在不增加患者不良反应率的前提下,可提高患者症状缓解率。

Objective:To study application value of rituximab combined with CHOP regimen in the treatment of aggressive B cell lymphoma.Methods:102 patients were selected,randomly divided into the routine group and the combination group ,were treatment with CHOP regimen and Mei Luohua combined with CHOP regimen,to evaluate the curative effective rate and adverse reaction rate.Results:The effectiveness of the combined treatment group (88. 24%)was higher than that of conventional group (66.67%)(P <0.05);the contrast differences of adverse reaction rates in the two groups (21.57%vs25.49%)had no statistical significance (P >0.05).Conclusion:Rituximab com-bined with CHOP in the treatment of aggressive B cell lymphoma,compared with the conventional scheme,in order not to increase the rate of adverse reactions of patients,patients can improve the symptom remission rate.